DBI is a pharmaceutical company (ANSM License M 12/203), dedicated to providing a small‑scale production
site
for pre-commercial batches (pre-clinical, clinical and pilot) of
injectable – liquid or lyophilized – drug products under isolators.
The benefits of DBI meet the needs of biotechnology and pharmaceutical
companies, including major groups,
for producing small injectable batches within a GMP production’s site.